Moleculin Biotech, Inc.
About Moleculin Biotech, Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$33.6M
- Total assets
- $22.1M
- Market cap
- $12.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $25.1M
- Operating income
- -$25.1M
- Income tax
- $0
- Net income
- -$33.6M
- EPS (basic)
- $-28.42
Balance sheet
- Total assets
- $22.1M
- Current assets
- $9.7M
- Total liabilities
- $7.1M
- Current liabilities
- $6.9M
- Shareholders’ equity
- $15.0M
Cash flow
- Operating cash flow
- -$22.7M
- Investing cash flow
- -$4.6M
- Financing cash flow
- $27.3M
- Net cash flow
- -$51.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $12.8M
- Shares outstanding
- 5.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 2, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $33.6M in FY2025.
- Trading 91% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Moleculin Biotech, Inc..
Write a review
News about Moleculin Biotech, Inc.
News & sentiment via Polygon.io
